Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Heiblig · SciRah

Researcher profile · Semantic Scholar

M. Heiblig

Share profile

M. Heiblig — researcher profile on SciRah

h-index: 25
Works: 215
Citations: 2,706

Most-cited papers

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Eunice S. Wang, G. Issa, Harry P. Erba, Jessica K. Altman +32 more
2024The Lancet Oncology107 citations
Semantic Scholar
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Martha L. Arellano, M. Thirman, J. Dipersio, M. Heiblig +32 more
2025Blood85 citations Open access
Semantic Scholar
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
J. Hadjadj, Yann Nguyen, D. Mouloudj, R. Bourguiba +69 more
2024Annals of the Rheumatic Diseases70 citations
Semantic Scholar
PFMG2025–integrating genomic medicine into the national healthcare system in France
Caroline Abadie, Aldja Abderrahmane, Ouarda Abdous, Carine Abel +496 more
2025The Lancet Regional Health - Europe61 citations Open access
Semantic Scholar
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML
Eunice S. Wang, P. Montesinos, James M. Foran, Harry P. Erba +33 more
2025Journal of Clinical Oncology51 citations Open access
Semantic Scholar
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
A. Mékinian, S. Georgin-lavialle, M. Ferrada, S. Savić +54 more
2025Arthritis & Rheumatology38 citations Open access
Semantic Scholar
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group.
V. Jachiet, O. Kosmider, Maxime Beydon, J. Hadjadj +50 more
2025Blood37 citations Open access
Semantic Scholar
Clinical features in VEXAS syndrome: a systematic review
A. Al-Hakim, Scott Goldberg, S. Gaillard, M. Heiblig +2 more
2025Rheumatology36 citations Open access
Semantic Scholar
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
U. Platzbecker, Lionel Adès, P. Montesinos, E. Ammatuna +45 more
2025Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Nicolas Gazeau, D. Beauvais, R. Tilmont, M. Srour +18 more
2025Leukemia22 citations Open access
Semantic Scholar
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study.
C. Lachowiez, M. Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier-Tardy +28 more
2025Blood Cancer Discovery19 citations
Semantic Scholar
Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome
S. Ganesan, Rebecca M. Murray, Jesus Sotelo, Elliot O. Eton +22 more
2024bioRxiv18 citations Open access
Semantic Scholar
Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia
N. Daver, J. Zeidner, Justin M. Watts, J. Yuda +34 more
2025Blood17 citations
Semantic Scholar
Indications and contraindications to platelet‐rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections)
Florent Eymard, K. Louati, É. Noel, R. Abouqal +30 more
2025Knee Surgery, Sports Traumatology, Arthroscopy14 citations Open access
Semantic Scholar
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders.
D. Fandrei, Jean Pegliasco, Florence Pasquier, Nathalie Ibrahim +30 more
2025Clinical Cancer Research14 citations
Semantic Scholar
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
M. Hunault, C. Pautas, S. Bertoli, P. Dumas +34 more
2025NEJM Evidence13 citations
Semantic Scholar
Neurological manifestations in patients with VEXAS syndrome
C. Bert-Marcaz, E. Fortanier, A. Briantais, B. Faucher +111 more
2025Journal of Neurology11 citations
Semantic Scholar
Ziftomenib in relapsed/refractory (R/R) NPM1 -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.
E. Wang, P. Montesinos, G. Issa, James M. Foran +16 more
2025Journal of Clinical Oncology10 citations
Semantic Scholar
Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study
C. Lachowiez, A. Kaempf, J. Othman, S. Yun +44 more
2025Blood9 citations
Semantic Scholar
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies
I. Mosialou, A. Ali, Rossella Labella, B. Bisikirska +30 more
2025Cancer Cell8 citations Open access
Semantic Scholar
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia
D. Lebon, A. da Rocha, B. Cassinat, M. Heiblig +18 more
2025Leukemia7 citations
Semantic Scholar
A Clinicopathological Description of Kidney Features in VEXAS Syndrome
Martin Mathurin, Pierre Hirsch, V. Jachiet, J. Hadjadj +33 more
2024Kidney International Reports7 citations Open access
Semantic Scholar
Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study
I. Aldoss, G. Issa, J. Blachly, M. Thirman +24 more
2025Blood6 citations
Semantic Scholar
Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations.
Ludovic Gabellier, Enzo Bosetta, M. Heiblig, J. Sarry
2025Trends in Cancer6 citations
Semantic Scholar
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.
Nicolas Duployez, Romane Joudinaud, A. Boudry, M. Hunault +41 more
2026Blood5 citations Open access
Semantic Scholar
Efficacy of erythroid‐stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group
M. Heiblig, V. Jachiet, J. Hadjadj, Lin-Pierre Zhao +9 more
2025HemaSphere5 citations Open access
Semantic Scholar
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study
T. Eviatar, D. Capelusnik, C. Campochiaro, Valentin Lacombe +32 more
2025Arthritis & Rheumatology5 citations Open access
Semantic Scholar
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study
Josquin Moraly, J. Rossignol, C. Rouzaud, Thomas Gabas +41 more
2024American journal of hematology/oncology5 citations Open access
Semantic Scholar
Histological characterization of liver involvement in systemic mastocytosis
J. Rossignol, Danielle Canioni, A. Aouba, Cristina Bulai-Livideanu +53 more
2024Liver international (Print)5 citations Open access
Semantic Scholar
Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome
Lin-Pierre Zhao, O. Kosmider, M. Heiblig, T. Moulinet +68 more
2026Leukemia4 citations
Semantic Scholar
Characterizing VEXAS syndrome in women: Findings from an international multicenter study
Rim Bourguiba, Valentin Lacombe, David B. Beck, E. Martín-Nares +15 more
2025Journal of Internal Medicine4 citations
Semantic Scholar
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Curtis A Lachowiez, J. Zeidner, Jad Othman, A. Kaempf +46 more
2026Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience
M. Heiblig, A. Plesa, Juliet Tantot, Y. Jamilloux +2 more
2025British Journal of Haematology3 citations Open access
Semantic Scholar
Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
Emmanuelle Tavernier, J. Cornillon, Zofia Gross, Gaspar Aspas Requena +15 more
2024Blood3 citations
Semantic Scholar
Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
Sophie Park, B. Slama, Marius Moldovan, D. Rombaut +23 more
2024Blood3 citations
Semantic Scholar
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin
M. Heiblig, C. Gourguechon, Philippe Guilpain, Cristina Bulai-Livideanu +54 more
2024American journal of hematology/oncology3 citations Open access
Semantic Scholar
Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
M. Heiblig, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier +15 more
2024Blood3 citations
Semantic Scholar
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.
Loic Vasseur, M. Duchmann, Nicolas Duployez, Emmanuel Raffoux +27 more
2026Leukemia2 citations
Semantic Scholar
Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study
Martha L. Arellano, M. Thirman, John F. DiPersio, M. Heiblig +32 more
2025Blood2 citations
Semantic Scholar
AML-111: Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)
I. Aldoss, G. Issa, J. Blachly, M. Thirman +24 more
2025Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Establishing a consensus definition of VEXAS flare for clinical research
L. Weeks, Danielle Hammond, S. Savic, M. Heiblig +10 more
2025Rheumatology2 citations Open access
Semantic Scholar
Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups
Christian Récher, C. Pautas, S. Bertoli, P. Dumas +38 more
2025Blood2 citations
Semantic Scholar
Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia
Urbain Tauveron-Jalenques, K. Sarr, Romain Guièze, C. Giordano +5 more
2024Annals of Hematology2 citations
Semantic Scholar
Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group
M. Heiblig, V. Jachiet, J. Hadjadj, Lin-Pierre Zhao +10 more
2024Blood2 citations
Semantic Scholar
Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study
O. Hermine, O. Debeaupuis, G. Damaj, J. Lübke +64 more
2026Journal of Hematology & Oncology1 citations Open access
Semantic Scholar
Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasms
G. Antherieu, H. Rezigue, Marie-Odile Geay-Baillat, Sandrine Loron +14 more
2025Blood1 citations
Semantic Scholar
Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
R. Stammler, Peter Chen, O. Debeaupuis, Lin-Pierre Zhao +43 more
2025HemaSphere1 citations Open access
Semantic Scholar
Odyssey: A first-in-human study of the aldehyde dehydrogenase (ALDH) inhibitor abd-3001 in patients with refractory/relapsed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
M. Heiblig, L. Benajiba, J. Colle, Sandrine Loron +12 more
2025Blood1 citations
Semantic Scholar
Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline
P. Dumas, Mathieu Leclerc, M. Hunault, Emmanuelle Tavernier +41 more
2025Blood1 citations
Semantic Scholar
Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo
P. Peterlin, M. Heiblig, S. Morisset, S. Bertoli +33 more
2025Blood1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

O. Kosmider×12
Invite
O. Kosmider — researcher profile on SciRah
S. Georgin-lavialle×12
Invite
S. Georgin-lavialle — researcher profile on SciRah
T. Comont×11
Invite
T. Comont — researcher profile on SciRah
B. Terrier×11
Invite
B. Terrier — researcher profile on SciRah

×10

Invite

P. Peterlin — researcher profile on SciRah

Invite

V. Jachiet — researcher profile on SciRah

Nicolas Duployez×9

Invite

Nicolas Duployez — researcher profile on SciRah

C. Papayannidis×8

Invite

C. Papayannidis — researcher profile on SciRah

Valentin Lacombe×8

Invite

Valentin Lacombe — researcher profile on SciRah

Invite

P. Sujobert — researcher profile on SciRah

Martin Carré×8

Invite

Martin Carré — researcher profile on SciRah

Invite

E. Raffoux — researcher profile on SciRah